Serum microRNA‑592 serves as a novel potential biomarker for early diagnosis of colorectal cancer

Pan,Zhenguo; Miao,Lin

doi:10.3892/ol.2020.11682

Serum microRNA‑592 serves as a novel potential biomarker for early diagnosis of colorectal cancer

Authors:
- Zhenguo Pan
- Lin Miao
View Affiliations

Affiliations: Department of Gastroenterology, Institute of Digestive Endoscopy and Medical Center for Digestive Diseases, Second Afﬁliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210011, P.R. China
Published online on: May 28, 2020 https://doi.org/10.3892/ol.2020.11682
Pages: 1119-1126
Copyright: © Pan et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Colorectal cancer (CRC) is the second leading cause of cancer‑associated mortality worldwide. Currently, available diagnostic biomarkers are neither sensitive nor specific. Thus, the present study aimed to identify novel circulating microRNAs (miRNAs) as biomarkers for the early diagnosis of CRC. All samples were provided by The Second Afﬁliated Hospital of Nanjing Medical University (Nanjing, China). Analysis of the GSE108153 and GSE55139 datasets, downloaded from the Gene Expression Omnibus (GEO) database was performed using the online tool, GEO2R. Reverse transcription‑quantitative PCR was performed to determine miR‑592 expression in CRC tissues, cells and serums of patients. Subsequently, the diagnostic value of serum miR‑592 was assessed via receiver operating characteristic (ROC) curve analysis. Both the assessment of clinical samples and bioinformatics analysis demonstrated that miR‑592 expression levels were significantly upregulated in the tissues and serum of patients with CRC, suggesting that elevated serum miR‑592 may be tumor‑derived. ROC analysis indicated that serum miR‑592 levels may differentiate patients with early stage CRC and advanced adenoma from healthy individuals, with area under the curve values of 0.801 and 0.747, respectively. Taken together, the results of the present study suggest that serum miR‑592 may be implicated as a potential biomarker for the early diagnosis of CRC.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Smith RA, von Eschenbach AC, Wender R, Levin B, Byers T, Rothenberger D, Brooks D, Creasman W, Cohen C, Runowicz C, et al: American Cancer Society guidelines for the early detection of cancer: Update of early detection guidelines for prostate, colorectal, and endometrial cancers. Also: Update 2001-testing for early lung cancer detection. CA Cancer J Clin. 51:38–75; quiz 77–80. 2001. View Article : Google Scholar : PubMed/NCBI
3	Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H, Jarvinen H and Haglund C: CEA, CA 242, CA 19-9, CA 72-4 and hCGbeta in the diagnosis of recurrent colorectal cancer. Tumour Biol. 25:228–234. 2004. View Article : Google Scholar : PubMed/NCBI
4	Hassan C, Pickhardt PJ, Laghi A, Kim DH, Zullo A, Iafrate F, Di Giulio L and Morini S: Computed tomographic colonography to screen for colorectal cancer, extracolonic cancer, and aortic aneurysm: Model simulation with cost-effectiveness analysis. Arch Intern Med. 168:696–705. 2008. View Article : Google Scholar : PubMed/NCBI
5	Liu X, Chen X, Zeng K, Xu M, He B, Pan Y, Sun H, Pan B, Xu X and Xu T: DNA-methylation-mediated silencing of miR-486-5p promotes colorectal cancer proliferation and migration through activation of PLAGL2/IGF2/β-catenin signal pathways. Cell Death Dis. 9:10372018. View Article : Google Scholar : PubMed/NCBI
6	Han LC, Wang H, Niu FL, Yan JY and Cai HF: Effect miR-214-3p on proliferation and apoptosis of breast cancer cells by targeting survivin protein. Eur Rev Med Pharmacol Sci. 23:7469–7474. 2019.PubMed/NCBI
7	Wei YQ, Jiao XL, Zhang SY, Xu Y, Li S and Kong BH: MiR-9-5p could promote angiogenesis and radiosensitivity in cervical cancer by targeting SOCS5. Eur Rev Med Pharmacol Sci. 23:7314–7326. 2019.PubMed/NCBI
8	Wu HY, Wei Y and Pan SL: Down-regulation and clinical significance of miR-7-2-3p in papillary thyroid carcinoma with multiple detecting methods. IET Syst Biol. 13:225–233. 2019. View Article : Google Scholar : PubMed/NCBI
9	An HJ, Park M, Kim J and Han YH: miR5191 functions as a tumor suppressor by targeting RPS6KB1 in colorectal cancer. Int J Oncol. Aug 30–2019.(Epub ahead of print). View Article : Google Scholar
10	Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, Peterson A, Noteboom J, O'Briant KC, Allen A, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA. 105:10513–10518. 2008. View Article : Google Scholar : PubMed/NCBI
11	Tang Y, Zhao Y, Song X, Song X, Niu L and Xie L: Tumor-derived exosomal miRNA-320d as a biomarker for metastatic colorectal cancer. J Clin Lab Anal. 33:e230042019. View Article : Google Scholar : PubMed/NCBI
12	Zhang Y, Sui J, Shen X, Li C, Yao W, Hong W, Peng H, Pu Y, Yin L and Liang G: Differential expression profiles of microRNAs as potential biomarkers for the early diagnosis of lung cancer. Oncol Rep. 37:3543–3553. 2017. View Article : Google Scholar : PubMed/NCBI
13	Liu X, Xu T, Hu X, Chen X, Zeng K, Sun L and Wang S: Elevated circulating miR-182 acts as a diagnostic biomarker for early colorectal cancer. Cancer Manag Res. 10:857–865. 2018. View Article : Google Scholar : PubMed/NCBI
14	Usuba W, Urabe F, Yamamoto Y, Matsuzaki J, Sasaki H, Ichikawa M, Takizawa S, Aoki Y, Niida S, Kato K, et al: Circulating miRNA panels for specific and early detection in bladder cancer. Cancer Sci. 110:408–419. 2019.PubMed/NCBI
15	Abu-Duhier FM, Javid J, Sughayer MA, Mir R, Albalawi T and Alauddin MS: Clinical significance of circulatory miRNA-21 as an efficient non-invasive biomarker for the screening of lung cancer patients. Asian Pac J Cancer Prev. 19:2607–2611. 2018.PubMed/NCBI
16	Imaoka H, Toiyama Y, Fujikawa H, Hiro J, Saigusa S, Tanaka K, Inoue Y, Mohri Y, Mori T, Kato T, et al: Circulating microRNA-1290 as a novel diagnostic and prognostic biomarker in human colorectal cancer. Ann Oncol. 27:1879–1886. 2016. View Article : Google Scholar : PubMed/NCBI
17	Lu JH, Zuo ZX, Wang W, Zhao Q, Qiu MZ, Luo HY, Chen ZH, Mo HY, Wang F, Yang DD, et al: A two-microRNA-based signature predicts first-line chemotherapy outcomes in advanced colorectal cancer patients. Cell Death Discov. 4:1162018. View Article : Google Scholar : PubMed/NCBI
18	Nonaka R, Nishimura J, Kagawa Y, Osawa H, Hasegawa J, Murata K, Okamura S, Ota H, Uemura M, Hata T, et al: Circulating miR-199a-3p as a novel serum biomarker for colorectal cancer. Oncol Rep. 32:2354–2358. 2014. View Article : Google Scholar : PubMed/NCBI
19	Ho AS, Kim S, Tighiouart M, Gudino C, Mita A, Scher KS, Laury A, Prasad R, Shiao SL, Ali N, et al: Association of quantitative metastatic lymph node burden with survival in hypopharyngeal and laryngeal cancer. JAMA Oncol. 4:985–989. 2018. View Article : Google Scholar : PubMed/NCBI
20	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
21	Zou X, Li M, Huang Z, Zhou X, Liu Q, Xia T and Zhu W: Circulating miR-532-502 cluster derived from chromosome X as biomarkers for diagnosis of breast cancer. Gene. 722:1441042020. View Article : Google Scholar : PubMed/NCBI
22	D'Antona P, Cattoni M, Dominioni L, Poli A, Moretti F, Cinquetti R, Gini E, Daffre E, Noonan DM, Imperatori A, et al: Serum miR-223: A validated biomarker for detection of early-stage non-small cell lung cancer. Cancer Epidemiol Biomarkers Prev. 28:1926–1933. 2019. View Article : Google Scholar : PubMed/NCBI
23	Cui Q: Significance of miR-27a and miR-31 in early diagnosis and prognosis of colorectal cancer. Oncol Lett. 18:3092–3096. 2019.PubMed/NCBI
24	Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW and Wender RC: Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 67:100–121. 2017. View Article : Google Scholar : PubMed/NCBI
25	Zhang J, Raju GS, Chang DW, Lin SH, Chen Z and Wu X: Global and targeted circulating microRNA profiling of colorectal adenoma and colorectal cancer. Cancer. 124:785–796. 2018. View Article : Google Scholar : PubMed/NCBI
26	Hou W, Zhang H, Bai X, Liu X, Yu Y, Song L and Du Y: Suppressive role of miR-592 in breast cancer by repressing TGF-β2. Oncol Rep. 38:3447–3454. 2017.PubMed/NCBI
27	He Y, Ge Y, Jiang M, Zhou J, Luo D, Fan H, Shi L, Lin L and Yang L: MiR-592 promotes gastric cancer proliferation, migration, and invasion through the PI3K/AKT and MAPK/ERK signaling pathways by targeting spry2. Cell Physiol Biochem. 47:1465–1481. 2018. View Article : Google Scholar : PubMed/NCBI
28	Li Z, Li B, Niu L and Ge L: miR-592 functions as a tumor suppressor in human non-small cell lung cancer by targeting SOX9. Oncol Rep. 37:297–304. 2017. View Article : Google Scholar : PubMed/NCBI
29	Gao S, Chen J, Wang Y, Zhong Y, Dai Q, Wang Q and Tu J: MiR-592 suppresses the development of glioma by regulating Rho-associated protein kinase. Neuroreport. 29:1391–1399. 2018. View Article : Google Scholar : PubMed/NCBI
30	Fu Q, Du Y, Yang C, Zhang D, Zhang N, Liu X, Cho WC and Yang Y: An oncogenic role of miR-592 in tumorigenesis of human colorectal cancer by targeting Forkhead Box O3A (FoxO3A). Expert Opin Ther Targets. 20:771–782. 2016. View Article : Google Scholar : PubMed/NCBI
31	Liu M, Zhi Q, Wang W, Zhang Q, Fang T and Ma Q: Up-regulation of miR-592 correlates with tumor progression and poor prognosis in patients with colorectal cancer. Biomed Pharmacother. 69:214–220. 2015. View Article : Google Scholar : PubMed/NCBI
32	Carpelan-Holmstrom M, Louhimo J, Stenman UH, Alfthan H and Haglund C: CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 22:2311–2316. 2002.PubMed/NCBI
33	Sun L, Liu X, Pan B, Hu X, Zhu Y, Su Y, Guo Z, Zhang G, Xu M, Xu X, et al: Serum exosomal miR-122 as a potential diagnostic and prognostic biomarker of colorectal cancer with liver metastasis. J Cancer. 11:630–637. 2020. View Article : Google Scholar : PubMed/NCBI
34	Zeng Z, Li Y, Pan Y, Lan X, Song F, Sun J, Zhou K, Liu X, Ren X, Wang F, et al: Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 9:53952018. View Article : Google Scholar : PubMed/NCBI
35	Wu B, Su S, Patil DP, Liu H, Gan J, Jaffrey SR and Ma J: Molecular basis for the specific and multivariant recognitions of RNA substrates by human hnRNP A2/B1. Nat Commun. 9:4202018. View Article : Google Scholar : PubMed/NCBI